Editor's Corner

Turing offers discounts instead of cutting controversial list price on Daraprim

Turing Pharmaceuticals promised to lower the price of its toxoplasmosis med, Daraprim, in response to growing backlash from lawmakers and the public after it bought the drug in August and jacked up its price by more than 5000%. Now the company is opting to negotiate discounts with hospitals rather than cut the drug's list price.

Xellia Pharma buys former Boehringer Ben Venue plant, once the poster child of quality failings

Denmark's Xellia Pharmaceuticals has bought the former Ben Venue plant, at one time the most notorious U.S. plant under FDA supervision, a facility responsible for dozens of recalls and a slew of drug shortages.

Mylan may soon find itself wrestling former target Perrigo for deals

Earlier this month, Perrigo shareholders spurned a hostile buyout attempt from Mylan. And now, the Netherlands-based company may have to go up against its former target if it wants to pursue a replacement buy.

Dr. Reddy's blasted in warning letter for hiding existence of testing lab from FDA

An FDA warning letter found that for years, Dr. Reddy's Laboratories was testing drug batches in a laboratory that the FDA was never told existed and often shipped to the U.S. products that had repeatedly failed tests for impurities.

Amgen nabs Kyprolis OK in Europe as U.S. competition mounts

Amgen's multiple myeloma treatment Kyprolis finally won approval in Europe--and with competition heating up across the pond, the go-ahead couldn't have come at a better time.